Nazione: Israele
Lingua: inglese
Fonte: Ministry of Health
DOCETAXEL
PFIZER PFE PHARMACEUTICALS ISRAEL LTD
L01CD02
SOLUTION FOR INFUSION
DOCETAXEL 10 MG / 1 ML
I.V
Required
HOSPIRA UK LTD, UK
DOCETAXEL
DOCETAXEL
Breast cancer: Docetaxel in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node- positive breast cancer. Docetaxel in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition. Docetaxel monotherapy is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent. Docetaxel in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumors overexpress HER2 and who previously have not received chemotherapy for metastatic disease. Docetaxel in combination with capecitabine is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline. Doxorubicin and cyclophosphamide followed by Docetaxel in combination with trastuzumab (AC-TH) is indicated for the adjuvant treatment of patients with HER2 over-expressing, node-positive or high risk node-negative, breast cancer. Docetaxel in combination with trastuzumab, and carboplatin (TCH) is indicated for the adjuvant treatment of patients with HER2 over-expressing, node-positive or high risk node-negative, breast cancer. Non-small cell lung cancer: Docetaxel is indicated for the treatment of patients with advanced non-small cell lung carcinoma. Ovarian Cancer: Docetaxel is indicated for treatment of metastatic carcinoma of the ovary after failure of first line or subsequent chemotherapy. Prostate cancer: Docetaxel in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.Esophageal cancer: Docetaxel for the treatment of esophageal cancer. Gastric cancer: Docetaxel for the treatment of advanced gastric cancer. Head and neck (SCCHN): Docetaxel as monotherapy in the treatment of patients with recurrent and/or metastasis squamos cell carcinoma of the head and neck after failure of a previous chemotherapy regimen. Docetaxel in combination with cisplatin and 5 fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck
2017-05-31
העדוה העדוה לע לע הרמחה הרמחה ( ( עדימ עדימ ןולעב )תוחיטב ןולעב )תוחיטב ל ל אפור אפור ךיראת 21.4.2013 םש רישכת תילגנאב DOCETAXEL HOSPIRA 10 MG/ML רפסמ םושיר 148.24.33345.00 םש לעב םושירה המראפהבונ מ"עב ספוט הז דעוימ טורפל תורמחהה דבלב ! םיטרפ לע םי/יונישה םי/שקובמה קרפ ןולעב טסקט יחכונ טסקט שדח SPECIAL WARNINGS AND SPECIAL PRECAUTIONS FOR USE Current text: In the case of severe neutropenia (<500 cells/mm 3 for 7 days or more) during a course of docetaxel therapy, a reduction in dose for subsequent courses of therapy or the use of appropriate symptomatic measures are recommended (see section “POSOLOGY AND METHOD OF ADMINISTRATION”). In patients treated with docetaxel in combination with cisplatin and 5-fluorouracil (TCF), febrile neutropenia and neutropenic infection occurred at lower rates when patients received prophylactic G-CSF. Patients treated with TCF should receive prophylactic G-CSF to mitigate the risk of complicated neutropenia (febrile neutropenia, prolonged neutropenia or neutropenic infection). Patients receiving TCF should be closely monitored (see section “POSOLOGY AND METHOD OF ADMINISTRATION” and “UNDESIRABLE EFFECTS“). Congestive heart failure: Patients should be monitored for symptoms of congestive Change to the following text: In the case of severe neutropenia (<500 cells/mm 3 for 7 days or more) during a course of docetaxel therapy, a reduction in dose for subsequent courses of therapy or the use of appropriate symptomatic measures are recommended (see section “POSOLOGY AND METHOD OF ADMINISTRATION”). In patients treated with docetaxel in combination with cisplatin and 5-fluorouracil (TCF), and docetaxel in combination with doxorubicin and cyclophosphamide (TAC), febrile neutropenia and neutropenic infection occurred at lower rates when patients received prophylactic G-CSF. Patients treated Leggi il documento completo
Docetaxel Hospira 10mg/ml LPD CC technical change 040219 2019-0047589 1 DOCETAXEL HOSPIRA ® 10 MG/ML 1. NAME OF THE MEDICINAL PRODUCT DOCETAXEL HOSPIRA ® 10 MG/ML. WARNING: TOXIC DEATHS, HEPATOTOXICITY, NEUTROPENIA, HYPERSENSITIVITY REACTIONS AND FLUID RETENTION THE INCIDENCE OF TREATMENT-RELATED MORTALITY ASSOCIATED WITH DOCETAXEL THERAPY IS INCREASED IN PATIENTS WITH ABNORMAL LIVER FUNCTION, IN PATIENTS RECEIVING HIGHER DOSES, AND IN PATIENTS WITH NON-SMALL CELL LUNG CARCINOMA AND A HISTORY OF PRIOR TREATMENT WITH PLATINUM-BASED CHEMOTHERAPY WHO RECEIVE DOCETAXEL AS A SINGLE AGENT AT A DOSE OF 100 MG/M2. DOCETAXEL SHOULD NOT BE GIVEN TO PATIENTS WITH BILIRUBIN > UPPER LIMIT OF NORMAL (ULN), OR TO PATIENTS WITH AST AND/OR ALT >1.5 × ULN CONCOMITANT WITH ALKALINE PHOSPHATASE >2.5 × ULN. PATIENTS WITH ELEVATIONS OF BILIRUBIN OR ABNORMALITIES OF TRANSAMINASE CONCURRENT WITH ALKALINE PHOSPHATASE ARE AT INCREASED RISK FOR THE DEVELOPMENT OF GRADE 4 NEUTROPENIA, FEBRILE NEUTROPENIA, INFECTIONS , SEVERE THROMBOCYTOPENIA, SEVERE STOMATITIS, SEVERE SKIN TOXICITY, AND TOXIC DEATH. PATIENTS WITH ISOLATED ELEVATIONS OF TRANSAMINASE >1.5 × ULN ALSO HAD A HIGHER RATE OF FEBRILE NEUTROPENIA GRADE 4 BUT DID NOT HAVE AN INCREASED INCIDENCE OF TOXIC DEATH. BILIRUBIN, AST OR ALT, AND ALKALINE PHOSPHATASE VALUES SHOULD BE OBTAINED PRIOR TO EACH CYCLE OF DOCETAXEL THERAPY. DOCETAXEL THERAPY SHOULD NOT BE GIVEN TO PATIENTS WITH NEUTROPHIL COUNTS OF <1500 CELLS /MM. IN ORDER TO MONITOR THE OCCURRENCE OF NEUTROPENIA, WHICH MAY BE SEVERE AND RESULT IN INFECTION, FREQUENT BLOOD CELL COUNTS SHOULD BE PERFORMED ON ALL PATIENTS RECEIVING DOCETAXEL. SEVERE HYPERSENSITIVITY REACTIONS CHARACTERIZED BY GENERALIZED RASH/ERYTHEMA, HYPOTENSION AND/OR BRONCHOSPASM, OR VERY RARELY FATAL ANAPHYLAXIS, HAVE BEEN REPORTED IN PATIENTS WHO RECEIVED A 3-DAY DEXAMETHASONE PREMEDICATION. HYPERSENSITIVITY REACTIONS REQUIRE IMMEDIATE DISCONTINUATION OF THE DOCETAXEL INFUSION AND ADMINISTRATION OF APPROPRIATE THERAPY. DOCETAXEL MUST NOT BE GIVEN TO PATIENT Leggi il documento completo